There are 3397 resources available
Invited Discussant LBA78 and 1512MO
Presenter: Hanneke van Laarhoven
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
Invited Discussant 1022MO, 1023MO and 1024MO
Presenter: Marco Donia
Session: Mini oral session - Investigational immunotherapy
Resources:
Slides
Webcast
Conclusion
Presenter: Barbara Moss
Session: The importance of secondary prevention: Early detection and screening programmes
Resources:
Slides
Webcast
Q&A
Presenter: Jean-Yves Blay
Session: Presidential 1
Resources:
Webcast
LBA4 - Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
Presenter: Herbert Ho Fung Loong
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA79 - GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Presenter: Xiaotian Zhang
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
1025MO - Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors
Presenter: Thomas Marron
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
LBA5 - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
Presenter: Nicolas Girard
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA80 - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Presenter: Rui-Hua Xu
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
1026MO - A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
Presenter: Luo Huiyan
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast